- Enovo Life Sciences, led by Mario Philips and Roel Gordijn, has been launched with financial backing from Warburg Pincus to focus on acquisitions in the biologics and advanced therapies markets.
- The platform aims to build a market-leading life sciences business through targeted acquisitions and investments, supporting innovation and growth.
Enovo Life Sciences has been launched by industry veterans Mario Philips and Roel Gordijn in partnership with Warburg Pincus, a global growth investor. The new platform will focus on acquiring companies in the biologics and advanced therapies markets, with the aim of building a market-leading life sciences business. Warburg Pincus is supporting the venture through its $17.3 billion flagship fund, WP GG 14.
Philips and Gordijn bring over 50 years of combined experience in the life sciences industry. They previously played key roles in the growth of Polyplus, a provider of upstream solutions for cell and gene therapies, before its sale to Sartorius Stedim Biotech for €2.4 billion. Philips, based in Belgium, has held executive roles at Danaher/Pall Biotech and ATMI Life Sciences, while Gordijn, based in the Netherlands, has held senior positions at Lonza and Danaher/Pall Biotech.
“Enovo Life Sciences will focus on acquiring companies with proven growth potential to build a scaled platform that drives innovation for customers and patients,” said Philips. “With Warburg Pincus’ backing, we are well-positioned to invest in these opportunities.”
The platform’s global approach will target businesses across the U.S. and Europe. Warburg Pincus, which has invested over $18 billion in healthcare companies, supports the initiative through its global network, with teams in London and New York.
Overview of outsourcing trends 
